good to see they played that card with the intra-cellular expansion release leading into the TIDES conference - if you look at the link i posted for it on the other thread it's got every big name R&D pharma present eyeing peptide developments.
Many will take the below as Roche having just advanced the collaboration with PYC after validating these "completely new structural families, bearing no resembelence to previously identified cell-penetrating peptides", and now have the option to license one. They are also now targeting the blood-brain barrier with this candidate.
They will be paying attention - based on limited success from others on these targets & the fact one of their rivals is heads up :-)
PYC Price at posting:
6.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)